Hong Jun Liang
Director/Board Member bij BEIJING STRONG BIOTECHNOLOGIES,INC.
Profiel
Hong Jun Liang is currently the Vice Chairman at Beijing Strong Biotechnologies, Inc. and Director at Fuzhou Maixin Biotech Co., Ltd.
Previously, he served as the Chairman-Supervisory Board at Shanghai Shyndec Pharmaceutical Co., Ltd.
and as a Director at Jiangsu Hengrui Pharmaceuticals Co., Ltd.
from 2018 to 2020.
Actieve functies van Hong Jun Liang
| Bedrijven | Functie | Begin |
|---|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Director/Board Member | 13-08-2020 |
Fuzhou Maixin Biotech Co., Ltd.
 Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Director/Board Member | 15-09-2020 |
Eerdere bekende functies van Hong Jun Liang
| Bedrijven | Functie | Einde |
|---|---|---|
| JIANGSU HENGRUI MEDICINE CO., LTD. | Director/Board Member | 01-01-2020 |
| SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Chairman | 15-11-2019 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| JIANGSU HENGRUI MEDICINE CO., LTD. | Health Technology |
| SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Health Technology |
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Health Services |
